Sector News

Teva eyes 'much larger' specialty buy in 2017

January 12, 2016
Life sciences

After watching months of pharma’s M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan’s generics business. And it may not be finished in the dealmaking arena.

As CEO Erez Vigodman told listeners during a Monday session at the J.P. Morgan Healthcare Conference, down the line, Teva could “entertain a much larger transaction on the specialty front.”

“I don’t want to rule out the possibility that we might pursue larger deals going forward if the right ones show themselves,” he said.

Don’t expect it to happen any time in the near future, though. If 2014 was for getting the company’s “house in order” and 2015 was for transformation with the Allergan deal, than 2016 will be about assimilation and integration, Vigodman said. 2017 is the earliest he could see the company shifting gears and moving to “the next phase to the grand story of Teva”–and there is a next phase in that story, he assured investors.

For now, Teva is in the middle of preintegration planning with Allergan’s generics team, which will come over after the companies close the $40.5 billion transaction they struck in July. The company has internally announced the top three layers of generics leadership, and it’s “working very closely” with the FTC to identify what products it’ll need to divest for antitrust reasons, generics CEO Siggi Olafsson said Monday.

Meanwhile, the Israeli pharma is negotiating with up to 5 potential buyers for those products, so it will “have the opportunity of moving quickly” when it gets word from the FTC, he said. Analysts have said one-time target Mylan could benefit from Teva’s castoffs as it jettisons assets that could be worth up to $1 billion.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.